The Evolving Castration-Resistant Prostate Cancer Treatment Landscape

Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.

EP: 1.A 57-Year-Old Man with Nonmetastatic Castration-Resistant Disease

EP: 2.Reviewing the Standard of Care for Patients with Nonmetastatic Castration-Resistant Disease

EP: 3.The Use of Darolutamide in Patients with Castration-Resistant Prostate Cancer

Now Viewing

EP: 4.The Evolving Castration-Resistant Prostate Cancer Treatment Landscape

Related Videos